Validity and Characterization of Time to Symptom Resolution Outcome Measures in the ACTIV-2/A5401 Outpatient COVID-19 Treatment Trial

By sjmartinez • August 31, 2023

Chew KW, Moser C, Yeh E, Wohl DA, Daar ES, Ritz J, Javan AC, Eron JJ, Currier JS, Smith DM, Hughes MD; ACTIV-2/A5401 Study Team. Validity and Characterization of Time to Symptom Resolution Outcome Measures in the ACTIV-2/A5401 Outpatient COVID-19 Treatment Trial. J Infect Dis. 2023 Aug 31;228(Supplement_2):S83-S91. doi: 10.1093/infdis/jiad300. PMID: 37650237; PMCID: PMC10469584.

Tags: ACTIV-2, covid-19, Harbor UCLA, Infectious Diseases, internal validity, patient-reported outcomes, Publications, symptom diary, time to symptom resolution

Related Posts

Randomized, Multicenter Study to Assess the Effects of Different Doses of Sildenafil on Mortality in Adults With Pulmonary Arterial Hypertension

Hoeper MM, Ewert R, Jansa P, Sirenko Y, Skride A, Balagtas C, Hackley S, Vogt S, Abreu P, Haughie S, Hassan T, Oudiz RJ. Randomized,[...]

Individualized Risk for CKD Progression among US Adults

Tio MC, Butler J, Zhu X, Obi Y, Yen TE, Kalantar-Zadeh K, Streja E, Dossabhoy NR, Hall ME, Shafi T. Individualized Risk for CKD Progression[...]

Safety, Efficacy, and Pharmacokinetics of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies BMS-986414 (C135-LS) and BMS-986413 (C144-LS) Administered Subcutaneously in Non-Hospitalized Persons with COVID-19 in a Phase 2 Trial

Corado KC, Chew KW, Giganti MJ, Mu Y, Fletcher CV, Currier JS, Daar ES, Wohl DA, Li JZ, Moser CB, Ritz J, Javan AC, Neytman[...]